Global Pertussis Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: July 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Pertussis Market was valued at $5.2 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 4.2% CAGR, to an estimated market size of $6.4 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global pertussis market encompasses the development, production, and distribution of vaccines (primarily DTaP and Tdap) and therapeutic treatments (antibiotics and supportive care) used to prevent and manage infections caused by the Bordetella pertussis bacterium. The scope includes routine pediatric immunization, adolescent and adult booster programs, and maternal vaccination strategies, while excluding general respiratory treatments not specific to whooping cough.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Pertussis Market in the period 2025-30:
- The rising incidence of pertussis and periodic outbreaks are driving a significant increase in demand for booster doses across adolescent and adult populations.
- There is a global transition toward acellular vaccines (aP) over whole-cell formulations to reduce the frequency of adverse injection-site reactions.
- Increased focus on maternal immunization programs is being prioritized by health organizations to provide passive immunity to newborns during their most vulnerable period.
- The widespread adoption of combination vaccines, such as DTaP-IPV-Hib, is improving patient compliance and streamlining national immunization schedules.
- Advancements in diagnostic technologies, particularly highly sensitive PCR assays, are enabling earlier detection and more effective outbreak management.
- Expanding government funding and public-private partnerships in emerging economies are significantly broadening vaccine accessibility in underserved regions.
- Persistent vaccine hesitancy and the waning immunity associated with current acellular formulations remain the primary challenges to achieving total herd immunity.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Asia-Pacific
- Europe
- Rest of World
Segments
- Acellular Vaccines
- Whole-cell Vaccines